Therapy for multiple sclerosis with monoclonal antibodies: Updated recommendations for the use of natalizumab in the framework of an expert's meeting;Therapie der multiplen sklerose mit monoklonalen antikörpern: Aktualisierte empfehlungen zum umgang mit natalizumab im rahmen eines expertenmeetings

Aktuelle Neurologie

Volumn 38, Issue 1, 2011, Pages 2-11

  Hartung, H P ^a   Berger, J ^b   Wiendl, H ^c   Meier, U ^d   Stangel, M ^e   Aktas, O ^a   Kieseier, B ^a   Radu E W ^f   Buttmann, M ^g   Gold, R ^h  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d Berufsverband Deutscher Neurologen   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h ST JOSEF HOSPITAL   (Germany)

Author keywords

immunotherapy; monoclonal antibodies; multiple sclerosis; natalizumab; PML

Indexed keywords

NATALIZUMAB;

ALGORITHM; CLINICAL PRACTICE; DRUG USE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; OUTPATIENT; PATIENT SAFETY; REVIEW;

EID: 79951858172     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0030-1266063     Document Type: Review

References (66)

1. Gold R, Hartung H P., Hohlfeld R et al. Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: Ergebnisse und Empfehlungen einer Arbeitstagung des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft. Akt Neurol 2009 36 334-344
2. Meier U, Pöhlau D, Gold R et al. Versorgungsnetzwerke für innovative Immuntherapien. Akt Neurol 2009 36 331-333
3. Warnke C, Menge T, Hartung H P. et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010 67 923-930
4. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 2010 (in press)
5. Tan C S., Koralnik I J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010 9 425-437
6. Piccinni C, Sacripanti C, Poluzzi E et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 2010 66 199-206
7. Berger J R., Houff S A., Major E O. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009 1 583-589
8. Carson K R., Evens A M., Richey E A. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 113 4834-4840
9. Du Pasquier R A., Clark K W., Smith P S. et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 2001 7 318-322
10. Du Pasquier R A., Kuroda M J., Zheng Y et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004 127 1970-1978
11. del Pilar M M., Cravens P D., Winger R et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008 65 1596-1603
12. Marzocchetti A, Lima M, Tompkins T et al. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. Virology 2009 383 173-177
13. Krumbholz M, Meinl I, Kumpfel T et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008 71 1350-1354
14. Zohren F, Toutzaris D, Klarner V et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008 111 3893-3895
15. Warnke C, Smolianov V, Dehmel T et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2010
16. Houff S A., Berger J R. The bone marrow, B cells, and JC virus. J Neurovirol 2008 14 341-343
17. Lindberg R L., Achtnichts L, Hoffmann F et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008 194 153-164
18. Chen Y, Bord E, Tompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009 361 1067-1074
19. Jilek S, Jaquiery E, Hirsch H H. et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010 9 264-272
20. Brooks B R., Walker D L. Progressive multifocal leukoencephalopathy. Neurol Clin 1984 2 299-313
21. Berger J R., Pall L, Lanska D et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998 4 59-68
22. Boster A, Hreha S, Berger J R. et al. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 2009 66 593-599
23. Bernal-Cano F, Joseph J T., Koralnik I J. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 2007 13 474-476
24. Takeda S, Yamazaki K, Miyakawa T et al. Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia. Neuropathology 2009 29 485-493
25. Kleiter I, Schroder M, Lurding R et al. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. Mult Scler 2010 16 749-753
26. http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/Tysabri-A20-0029- Annex-IV.pdf Internet 2010
27. Clifford D B., De L A., Simpson D M. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010 9 438-446
28. Lindå H, Heijne A von, Major E O. et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009 361 1081-1087
29. http://tysabri.de/index.php?inhalt=informationen.materialien Internet 2010
30. Sailer M, Fazekas F, Gass A et al. [Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis]. Rofo 2008 180 994-1001
31. Langer-Gould A, Atlas S W., Green A J. et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005 353 375-381
32. Wenning W, Haghikia A, Laubenberger J et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009 361 1075-1080
33. Kleinschmidt-DeMasters B K., Tyler K L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005 353 369-374
34. Rudick R A., Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004 4 571-580
35. Tubridy N, Behan P O., Capildeo R et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999 53 466-472
36. Stuve O, Marra C M., Bar-Or A et al. Altered CD4+ / CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006 63 1383-1387
37. Khatri B O., Man S, Giovannoni G et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009 72 402-409
38. Hall C D., Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998 338 1345-1351
39. De L A., Ammassari A, Pezzotti P et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008 22 1759-1767
40. Kraemer C, Evers S, Nolting T et al. Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy. J Neurol 2008 255 526-531
41. Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009 53 1840-1849
42. Altschuler E L., Kast R E. The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses 2005 65 585-586
43. Lanzafame M, Ferrari S, Lattuada E et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009 17 35-37
44. Elphick G F., Querbes W, Jordan J A. et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004 306 1380-1383
45. Nukuzuma S, Nakamichi K, Nukuzuma C et al. Inhibitory effect of serotonin antagonists on JC virus propagation in a carrier culture of human neuroblastoma cells. Microbiol Immunol 2009 53 496-501
46. Chapagain M L., Verma S, Mercier F et al. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology 2007 364 55-63
47. Berger J R., Centonze D, Comi G et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010 68 409-411
48. Killestein J, Vennegoor A, Strijbis E M. et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010 68 392-395
49. West T W., Cree B A. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010 68 395-399
50. Lenhard T, Biller A, Mueller W et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2010 75 831-833
51. Shelburne III S A., Hamill R J., Rodriguez-Barradas M C. et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002 81 213-227
52. Miller R F., Isaacson P G., Hall-Craggs M et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 2004 108 17-23
53. Dhasmana D J., Dheda K, Ravn P et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008 68 191-208
54. Ruhwald M, Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS 2007 21 882-884
55. Autran B, Carcelain G, Li T S. et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997 277 112-116
56. Tan K, Roda R, Ostrow L et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009 72 1458-1464
57. Schroder A, Lee D H., Hellwig K et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010 67 1391-1394
58. Tyler K L. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010 68 271-274
59. Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010 68 295-303
60. Ryschkewitsch C F., Jensen P N., Monaco M C. et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010 68 384-391
61. Warnke C, Adams O, Hartung H P. et al. Comment to Rudick, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010 (in press) 68 304-310
62. Rudick R A., O'Connor P W., Polman C H. et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010 68 304-310
63. Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009 66 403-406
64. Phan Ba R, Bisig B, Deprez M et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2010 (in press)
65. Bozic C, Cristiano L M., Hyde R et al. Utilization and Safety of Natalizumab in Patients with Relapsing Multiple Sclerosis. [Abstract]. Gothenburg ECTRIMS 2010 2010 P893
66. Vennegoor A, Wattjes M P., van Munster E TL et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011 76 574-576